The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis
Abstract More promising, effective, and less-invasive biomarkers for PD(L)-1 targeted responses, immune-related adverse events (irAEs), and prognosis are being explored. We conducted a single-center retrospective study in pan-cancer patients with anti-PD(L)-1 monotherapy. Observational endpoints inc...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-05-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-02597-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849731058258411520 |
|---|---|
| author | Xiaomin Fu Fanghui Li Hongqin You Benling Xu Tingjie Wang Peng Qin Lu Han Yong Zhang Fang Zhang Lingdi Zhao Baozhen Ma Yiman Shang Yonghao Yang Zibing Wang Jinrong Qu Quanli Gao |
| author_facet | Xiaomin Fu Fanghui Li Hongqin You Benling Xu Tingjie Wang Peng Qin Lu Han Yong Zhang Fang Zhang Lingdi Zhao Baozhen Ma Yiman Shang Yonghao Yang Zibing Wang Jinrong Qu Quanli Gao |
| author_sort | Xiaomin Fu |
| collection | DOAJ |
| description | Abstract More promising, effective, and less-invasive biomarkers for PD(L)-1 targeted responses, immune-related adverse events (irAEs), and prognosis are being explored. We conducted a single-center retrospective study in pan-cancer patients with anti-PD(L)-1 monotherapy. Observational endpoints included treatment response, prognosis, and irAEs. Peripheral blood immunophenotypes were analyzed by Flow Cytometry. 104 patients were enrolled. Higher pretreatment percentages of CD3+CD4+ Th cells were associated with both responses (HR: 6.170, P = 0.034) and prognosis (HR: 1.930, P = 0.022). The higher baseline percentage of CD16+CD56+ NK cells was positively correlated with response (HR: 3.730, P = 0.050) and negatively related to irAEs (HR: 0.460, P = 0.012). Decreased pretreatment CD3+ T cell counts were related to more irAEs (HR: 0.970, P = 0.026), while the percentage of CD3+ T cells was negatively associated with prognosis (HR: 1.930, P = 0.022). The higher baseline cell counts of CD3+CD8+ CTL, CD19+ B, and the percentage of CD19+ B cells might be related to more irAEs (P < 0.05). Significant correlation between duration of treatment (DOT) and prognosis, irAE and outcome was also confirmed (P < 0.0001). Our findings confirmed multiple baseline circulating immunophenotype characteristics were related to PD(L)-1 targeted response, irAE onset, and prognosis. |
| format | Article |
| id | doaj-art-c7dff9181b54442cac0e490f35b693fa |
| institution | DOAJ |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-c7dff9181b54442cac0e490f35b693fa2025-08-20T03:08:40ZengNature PortfolioScientific Reports2045-23222025-05-0115111410.1038/s41598-025-02597-5The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosisXiaomin Fu0Fanghui Li1Hongqin You2Benling Xu3Tingjie Wang4Peng Qin5Lu Han6Yong Zhang7Fang Zhang8Lingdi Zhao9Baozhen Ma10Yiman Shang11Yonghao Yang12Zibing Wang13Jinrong Qu14Quanli Gao15Department of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalDepartment of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalGMP Laboratory of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalGMP Laboratory of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalDepartment of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalGMP Laboratory of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalGMP Laboratory of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalDepartment of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalDepartment of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalDepartment of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalDepartment of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalDepartment of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalDepartment of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalDepartment of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalDepartment of Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalDepartment of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalAbstract More promising, effective, and less-invasive biomarkers for PD(L)-1 targeted responses, immune-related adverse events (irAEs), and prognosis are being explored. We conducted a single-center retrospective study in pan-cancer patients with anti-PD(L)-1 monotherapy. Observational endpoints included treatment response, prognosis, and irAEs. Peripheral blood immunophenotypes were analyzed by Flow Cytometry. 104 patients were enrolled. Higher pretreatment percentages of CD3+CD4+ Th cells were associated with both responses (HR: 6.170, P = 0.034) and prognosis (HR: 1.930, P = 0.022). The higher baseline percentage of CD16+CD56+ NK cells was positively correlated with response (HR: 3.730, P = 0.050) and negatively related to irAEs (HR: 0.460, P = 0.012). Decreased pretreatment CD3+ T cell counts were related to more irAEs (HR: 0.970, P = 0.026), while the percentage of CD3+ T cells was negatively associated with prognosis (HR: 1.930, P = 0.022). The higher baseline cell counts of CD3+CD8+ CTL, CD19+ B, and the percentage of CD19+ B cells might be related to more irAEs (P < 0.05). Significant correlation between duration of treatment (DOT) and prognosis, irAE and outcome was also confirmed (P < 0.0001). Our findings confirmed multiple baseline circulating immunophenotype characteristics were related to PD(L)-1 targeted response, irAE onset, and prognosis.https://doi.org/10.1038/s41598-025-02597-5PD(L)-1 inhibitorMonotherapyResponseIrAEPrognosisBiomarker |
| spellingShingle | Xiaomin Fu Fanghui Li Hongqin You Benling Xu Tingjie Wang Peng Qin Lu Han Yong Zhang Fang Zhang Lingdi Zhao Baozhen Ma Yiman Shang Yonghao Yang Zibing Wang Jinrong Qu Quanli Gao The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis Scientific Reports PD(L)-1 inhibitor Monotherapy Response IrAE Prognosis Biomarker |
| title | The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis |
| title_full | The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis |
| title_fullStr | The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis |
| title_full_unstemmed | The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis |
| title_short | The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis |
| title_sort | baseline circulating immunophenotype characteristics associate with pd l 1 targeted treatment response irae onset and prognosis |
| topic | PD(L)-1 inhibitor Monotherapy Response IrAE Prognosis Biomarker |
| url | https://doi.org/10.1038/s41598-025-02597-5 |
| work_keys_str_mv | AT xiaominfu thebaselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT fanghuili thebaselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT hongqinyou thebaselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT benlingxu thebaselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT tingjiewang thebaselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT pengqin thebaselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT luhan thebaselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT yongzhang thebaselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT fangzhang thebaselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT lingdizhao thebaselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT baozhenma thebaselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT yimanshang thebaselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT yonghaoyang thebaselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT zibingwang thebaselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT jinrongqu thebaselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT quanligao thebaselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT xiaominfu baselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT fanghuili baselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT hongqinyou baselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT benlingxu baselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT tingjiewang baselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT pengqin baselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT luhan baselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT yongzhang baselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT fangzhang baselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT lingdizhao baselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT baozhenma baselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT yimanshang baselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT yonghaoyang baselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT zibingwang baselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT jinrongqu baselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis AT quanligao baselinecirculatingimmunophenotypecharacteristicsassociatewithpdl1targetedtreatmentresponseiraeonsetandprognosis |